News
In the second quarter of 2025, Myriad Genetics initiated a review of its long-range growth strategy. While the updated strategy, which is designed to drive accelerated growth and profitability by ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 and updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback